Project Name: Ticagrelor
Registration Classification:3+6
Formulations and specifications :Tablets: 90mg
Indications:For acute coronary syndrome ( unstable angina, non- ST -segment elevation myocardial infarction or ST -segment elevation myocardial infarction ) , including patients receiving drug therapy and percutaneous coronary intervention (PCI) treatment to reduce the incidence of thrombotic cardiovascular events.
Original Research Company:AstraZeneca
Progress :Pharmaceutical Research in progress
Category :Antithrombotic drugs